<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20261019071496N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-24</date_registration>
      <primary_sponsor>Rooyan Aqvida</primary_sponsor>
      <public_title>Bioequivalence study of Palbociclib capsule</public_title>
      <acronym></acronym>
      <scientific_title>Bioequivalence Study of Palbociclib 125 mg Hard Capsules of Rooyan Aqvida Compared to the Reference Drug In Iranian Healthy Volunteers</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>24</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>https://irct.ir/trial/94277</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: Randomization will be performed using statistical software, Blinding description: This study will be conducted using a double-blind design, in which both the participants and the data analyst will be unaware of the participants’ treatment allocation and the sequence in which the test and reference products are administered. To maintain blinding, the capsules of the test and reference products will be removed from their original packaging and placed in identical containers bearing unique codes. In addition, all blood samples collected during the study will be coded, and the data analyst will not have access to information regarding the participants’ treatment allocation until unblinding.</study_design>
      <phase>Bioequivalence</phase>
      <hc_freetext>A crossover bioequivalence study in 24 healthy volunteers.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, healthy volunteers will receive one 125 mg palbociclib capsule manufactured by Royan Aquiva orally with food. Blood samples will be collected for up to 72 hours post-dose, and plasma drug concentrations will be measured. Following a 14-day washout period, participants will receive the intervention 2 product. Intervention 2: Intervention group: In this group, 12 healthy volunteers will receive a single oral dose of one 125 mg palbociclib capsule of the reference (brand-name) product with food. Blood samples will be collected for up to 72 hours post-dose, and plasma drug concentrations will be measured. Following a 14-day washout period, participants will receive the intervention 1 product.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is A specific plan for public sharing of de-identified individual participant data has not yet been established.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereshteh Bayat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 2660, School of Pharmacy, Shahid Beheshti Medical University, Valiasr Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996835113</zip>
        <telephone>+98 21 8866 5317</telephone>
        <email>fereshtehbayat@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fereshteh Bayat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 2660, School of Pharmacy, Shahid Beheshti Medical University, Valiasr Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1996835113</zip>
        <telephone>+98 21 8866 5317</telephone>
        <email>fereshtehbayat@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Iranian adults aged 18–50 years of either sex
A body weight of &gt;50 kg for males and &gt;45 kg for females, and a body mass index (BMI) of 18.5–30 kg/m²</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Any history of drug or food allergies
Use of any prescription medications, over-the-counter (OTC) medications, traditional medicines, dietary supplements, or consumption of fruits such as grapefruit, mango, dragon fruit, lemon, and orange within 14 days prior to screening or during the study
Pregnancy
Breastfeeding
Any underlying disease or clinically significant condition that, in the investigator’s judgment, may affect the participant’s safety, the interpretation of study results, or the metabolism and elimination of palbociclib</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, healthy volunteers will receive one 125 mg palbociclib capsule manufactured by Royan Aquiva orally with food. Blood samples will be collected for up to 72 hours post-dose, and plasma drug concentrations will be measured. Following a 14-day washout period, participants will receive the intervention 2 product.</i_keyword>
      <i_keyword>Intervention group: In this group, 12 healthy volunteers will receive a single oral dose of one 125 mg palbociclib capsule of the reference (brand-name) product with food. Blood samples will be collected for up to 72 hours post-dose, and plasma drug concentrations will be measured. Following a 14-day washout period, participants will receive the intervention 1 product.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Drug plasma concentration. Timepoint: Predose, 1, 2, 4, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 24, 36, 48, 72. Method of measurement: Liquid Chromatography with tandem mass spectrometry.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Maximum Plasma Concentration (Cmax). Timepoint: Predose, 1, 2, 4, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 24, 36, 48, 72. Method of measurement: Liquid Chromatography with tandem mass spectrometry.</sec_outcome>
      <sec_outcome>AUC (Area Under the Concentration-Time Curve). Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rooyan Aqvida</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-10-19</approval_date>
        <contact_name>Ethics committee of The Institute of Pharmaceutical Sciences, Tehran University of Medical Sciences</contact_name>
        <contact_address>Ethics committee of The Institute of Pharmaceutical Sciences, Tehran University of Medical Science, 16 Azar St. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
